Insider Buying: Savara Inc (NASDAQ:SVRA) CEO Acquires 28,700 Shares of Stock

Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls acquired 28,700 shares of the stock in a transaction that occurred on Monday, February 22nd. The stock was acquired at an average cost of $1.74 per share, with a total value of $49,938.00.

Savara stock traded up $0.20 during trading hours on Tuesday, reaching $1.93. The stock had a trading volume of 44,824 shares, compared to its average volume of 481,044. The company has a market cap of $104.49 million, a price-to-earnings ratio of -1.30 and a beta of 1.18. The business’s 50 day moving average price is $1.61 and its 200-day moving average price is $1.38. Savara Inc has a 52 week low of $1.00 and a 52 week high of $3.17. The company has a debt-to-equity ratio of 0.33, a current ratio of 12.61 and a quick ratio of 12.61.

Several institutional investors have recently modified their holdings of the company. Bank of America Corp DE lifted its position in Savara by 48.3% during the second quarter. Bank of America Corp DE now owns 20,603 shares of the company’s stock valued at $51,000 after acquiring an additional 6,708 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Savara by 16.7% during the 4th quarter. Rhumbline Advisers now owns 70,848 shares of the company’s stock valued at $81,000 after purchasing an additional 10,135 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Savara by 2.6% in the 4th quarter. Renaissance Technologies LLC now owns 399,900 shares of the company’s stock worth $460,000 after purchasing an additional 10,200 shares in the last quarter. Metropolitan Life Insurance Co NY acquired a new stake in shares of Savara in the 1st quarter worth $83,000. Finally, Brown Advisory Inc. grew its stake in Savara by 23.1% during the 4th quarter. Brown Advisory Inc. now owns 111,044 shares of the company’s stock worth $128,000 after buying an additional 20,854 shares during the last quarter. 40.66% of the stock is currently owned by hedge funds and other institutional investors.

SVRA has been the subject of several recent research reports. Zacks Investment Research lowered shares of Savara from a “buy” rating to a “hold” rating in a report on Wednesday, November 4th. HC Wainwright reduced their price objective on shares of Savara from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 15th. Finally, Evercore ISI initiated coverage on Savara in a research report on Monday, November 23rd. They set an “outperform” rating on the stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Read More: S&P/TSX Index

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with's FREE daily email newsletter.